EATG » Access

Access

Analysis of why drug prices are so high in the USA

The study The High Cost of Prescription Drugs in the United States - Origins and Prospects for Reform by Aaron S. Kesselheim Jerry Avorn, and Ameet Sarpatwari discusses the reasons why medicine prices are often incomprehensibly high, and keep…

Georgia launches new national strategy to eliminate hepatitis C

TBILISI - The Georgian Government has approved a National Strategy for the Elimination of Hepatitis C during a cabinet session on Tuesday (August 16). The new campaign will run until…

Antiretroviral treatment scale-up and TB mortality in high TB/HIV burden countries: an econometric analysis

Abstract Introduction Antiretroviral therapy (ART) reduces mortality in patients with active tuberculosis (TB), but the population-level relationship between ART coverage and TB mortality is untested. We estimated the reduction in…

Are we losing our passion as AIDS activists?

We’ve come a long way since the days when fighting for LGBT rights demanded action such as the Stonewall Riots. Or a critical need for HIV medications prompted protests blocking traffic…

Access to treatment for hepatitis C virus infection: time to put patients first

Summary Sound health policy puts patients first. Antiviral regimens approved in 2014 revolutionised treatment of hepatitis C virus (HCV) infection. Most patients can now be cured. These new regimens, however,…

Why are hepatitis C patients treated differently by NHS England?

NHS England’s decision to cap access to National Institute for Health and Care Excellence (NICE) approved hepatitis C treatments has been attributed to their cost. These antiviral medicines have led…

PROUD study closes leaving participants with no access to PrEP

On 29 July 2016, the PROUD study website announced that the study will close without being able to continue to provide participants with oral PrEP. The press release blames…

Universal treatment of MDR-TB is possible within current budgets with generic production

Generic production could make novel multidrug-resistant tuberculosis (MDR-TB) regimens available for US $53–507 per treatment course according to data presented at TB2016. To read the full article, click here.

High Court rules NHS England is responsible for funding PrEP

A judicial review in the High Court has ruled that NHS England is responsible for funding pre-exposure prophylaxis (PrEP) and decisively rebutted all the arguments used by NHS England to…

Betting on hepatitis C: how financial speculation in drug development influences access to medicines

Victor Roy and Lawrence King argue that the acquisition strategies of drug companies magnify development costs and leave the public paying twice—for research and high priced medicines To read the…